The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression. A new analysis of nearly 2000 patients with low-risk myelodysplastic syndrome (MDS) has ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Genome-wide chromatin accessibility profiling reveals how myelodysplastic syndrome (MDS) stem cells progressively lose normal stem-cell features and acquire myeloid progenitor-like characteristics.